Board changes

RNS Number : 0070E

e-Therapeutics plc

13 July 2016

 

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Board Update

Oxford, UK, 13 July 2016 - e-Therapeutics plc (AIM:ETX) announced today that Iain Ross has been appointed Executive Chairman and that he will take responsibility for all corporate and commercial discussions and lead the search for a new CEO.

In addition Steve Medlicott, CFO has been appointed Interim COO based in Oxford and Professor Trevor Jones, Director has agreed to work closely with, and take oversight of the Scientific team and lead an immediate and comprehensive project review.

Iain Ross, Chairman commented:
"I am confident that these organisational changes will ensure that we continue to develop the ongoing business. I would like to thank the institutional shareholders for their support during this period of transition and confirm that we have commenced the search for a new CEO."

-Ends-

Contacts:

e-Therapeutics plc Iain Ross, Chairman Steve Medlicott, Finance Director	Tel: [phone] www.etherapeutics.co.uk
Numis Securities Limited Michael Meade / Freddie Barnfield (Corporate Finance) James Black (Corporate Broking)	Tel: [phone] www.numis.com
Instinctif Partners Melanie Toyne Sewell	Tel: [phone] Email: [e-mail]

About e-Therapeutics plc

e-Therapeutics (AIM: ETX) is a drug discovery company with a proprietary discovery platform based on advances in network pharmacology and chemical biology.

 The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and anti-infectives. The platform is highly productive, yielding multiple potent and selective molecules at a much higher rate and more quickly than is reported for conventional drug discovery. 

e-Therapeutics has a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFα; ETS2400, Hedgehog pathway inhibition and ETS5200, broad spectrum antivirals. The Company has recently completed a phase IIb clinical trial for ETS6103, a drug to treat major depressive disorder.  

The Company is fully funded to advance its drug discovery programmes. It is based in Oxford and Newcastle, UK. For more information, visit www.etherapeutics.co.uk.  

 

END

 

 

BOAUUUURNVABAUR